

REMARKS

Claims 29-30 and 32-37 are now pending, upon entry of the amendment submitted above. Favorable reconsideration is respectfully requested.

As amended, the present invention relates to a mouse suitable as a model for atopic dermatitis, wherein the mouse is a NC/Nga mouse which has been sensitized with a mite extract on the ear(s) under a specific pathogen free environment, such that the animal displays at least one symptom of atopic dermatitis caused by the mite extract. See Claim 29.

The present invention also relates to a method of producing the mouse described above, and to a method of screening for an agent for effectiveness against atopic dermatitis using the mouse described above. See Claims 35 and 37, respectively.

The rejection under 35 U.S.C. §103(a) over Morita et al. in view of Yasue et al. is believed to be obviated by the amendment submitted above. These references fail to suggest the claimed mouse.

Claim 29 has been amended to specify, *inter alia*, that the mouse has been sensitized with a mite extract on the ear(s).

In contrast, Morita et al. describe a mouse that has skin lesions on its whole body. In Morita et al. there is no teaching or suggestion to apply mite or mite extract to the ear(s) of the mouse.

Because of this difference, the claimed mouse has an important advantage as compared to the mouse described by Morita et al. If the mouse described by Morita et al. is used for the screening of therapeutic agents, the efficacy of the agent is inevitably going to be assessed by a score as Horii et al. has done. However, this assay is qualitative and, therefore, less accurate. On the other hand, by screening using the mouse recited in Claim 29, the

BEST AVAILABLE COPY

**COPY**

efficacy of the therapeutic agent can be assessed easily and quantitatively by only measuring the thickness of the ear of the mouse.

In addition, the mouse of the present invention has been recognized as an important contribution in the art. Applicants enclose herewith a copy of the Abstract of General Meeting of the Japanese Society of Allergology held in November 2002 and an English translation thereof. Regarding the claimed mouse, the research group of Gifu Pharmaceutical University reported the following:

We considered this model as a severe dermatitis model with desquamation of epidermis. Repetitive stimulation by mite antigen induced Th2 elevation of Th1/Th2 balance with up-regulation of IgE production. From now on, the further analysis of pathogenesis of atopic dermatitis will be done using this model. (Presentation No. 375, Conclusion)

The dermatitis model repeatedly applied with mite antigen on the ears of NC/Nga mice showed the Th2 dependent background. It can be considered to be useful as an animal model reflecting the one aspect of atopic dermatitis. (Presentation No. 376, Conclusion)

Thus, the research group of Gifu Pharmaceutical University reported that the claimed mouse is useful as an animal model of atopic dermatitis and that group would recognize that the claimed mouse is superior to the mouse described by Morita et al.

As note above, Morita et al. fail to describe applying mite or mite extract to the ear(s) of the mouse. In addition, the mouse described by that reference does not provide the advantages of the claimed mouse discussed above. Yasue et al. not describe sensitizing the ear(s) of the mouse as claimed or the advantages of the claimed mouse, and, therefore, does not remedy the deficiencies of Morita et al. Therefore, the claimed mouse, method of making, and method of screening with the same are patentable over those references. Accordingly, Claims 29-30 and 32-37 are not obvious over Morita et al. in view of Yasue et al. Withdrawal of this ground of rejection is respectfully requested.

Applicants submit that the present application is in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Norman F. Oblon  
Attorney of Record  
Registration No. 34,618

**COPY**  
James J. Kelly, Ph.D.  
Registration No. 41,504

I:\atty\JK\0018-1098\O.AF.wpd



**22850**

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMA 11/98)

BEST AVAILABLE COPY

ATTORNEY DOCKET NO.: 0018-1098-0  
SERIAL NO.: 09/548,290

**MARKED-UP COPY**

Serial No.: 09/548,290  
Amendment Filed On: Herewith

**IN THE CLAIMS**

Claim 31 (Cancelled).

--29. (Amended) A mouse suitable as a model for atopic dermatitis, wherein the mouse is a NC/Nga mouse which has been sensitized [impregnated] with a mite extract on the ear(s) under a specific pathogen free environment, such that the animal displays at least one symptom of atopic dermatitis caused by the mite extract.

30. (Amended) The mouse of Claim 29, wherein said symptom is skin lesions on the ear(s) of the mouse.

32. (Amended) The mouse of Claim 30 [31], wherein the skin lesions are at least one member selected from the group consisting of erythema, edema, excoriation, and scaling.

33. (Amended) The mouse of Claim 30 [31], wherein the skin lesions are erythema.

35. (Amended) A method of producing the mouse of Claim 29 [21], comprising:  
maintaining a NC/Nga mouse in a Specific Pathogen Free environment and  
sensitizing [impregnating] the ear(s) of the mouse with the mite extract.

36. (Amended) The method of Claim 35 [25], wherein the animal is sensitized  
[impregnated] with the mite extract for at least 5 days.--

BEST AVAILABLE COPY

Attachment 2

# アレルギー

Japanese Journal of Allergology

第52回日本アレルギー学会総会

期 日 2002年11月22日(土) 23日(日) 24日(月)

会 場 パシフィコ横浜

会 長 佐藤 隆 敬 賀 山 崎 誠

BEST AVAILABLE COPY

Vol. 51

JAPANESE SOCIETY OF ALLERGOLOGY

No. 9-10

2002年10月

日本アレルギー学会

COPY

1000

### 373 FcεRIα 鎖特異的ヒト scFv 抗体フラグメントから Fab 抗体への抗体エンジニアリング

橋口周平<sup>1)</sup> 中島敏博<sup>2)</sup> 島岡正治<sup>2)</sup> 林 智博<sup>1)</sup>  
 吉永圭介<sup>1)</sup> 伊東祐二<sup>1)</sup> 杉村和久<sup>1)</sup>  
 (鹿児島大学 工学部 生体工学科<sup>1)</sup> 化血研<sup>2)</sup>)

昨年度のアレルギー学会でヒト FcεRIα 鎖特異的ヒト scFv 抗体フラグメントについて報告した。今回は scFv 抗体をもとに Fab 抗体への抗体エンジニアリングを行った。

【方法と結果】pCANTAB5E ファージミドベクターに組み込まれたヒト FcεRIα 鎖特異的ヒト scFv 抗体 (FcReS1) の scFv 遺伝子を鋳型として、5'/3'末端に SfiI/SfiI サイトを設けた VH 領域増幅用のプライマー、および XhoI/NotI サイトを設けた VL 領域を増幅用のプライマーを用いて PCR を行った。精製した VH および VL 遺伝子断片を pUC19 ベースの Fab 発現ベクターの SfiI サイトおよび XhoI/NotI サイトに順次クローニングし、Fab 発現用のベクターを作製した。得られた発現ベクターを大腸菌 JM83 に組み込み、Fab 抗体を発現させた。この Fab 断片は、ヒト CH1 およびヒト Cκ で構成されており、H<sub>2</sub>L 間の S-S 結合部の Cys を Ser に置換してある。単離した Fab 抗体の抗原特異性を ELISA 法で調べたところ、可溶性 FcεRIα 鎖との結合活性が認められた。現在この FcεRIα 特異的 Fab 抗体の性状について検討している。

### 374 タクロリムス軟膏はマウスの発癌を著しく促進する

丹羽朝貞  
 (土佐清水病院)

盛んに使用され始めたタクロリムス軟膏 (FK506) は、元来臓器移植の拒否反応を抑える免疫抑制剤で、近年 FK506 を投与していた臓器移植患者千例中、CD4/CD8 の低下を伴った新しい固形癌が 7.2% の症例に発生した (Transplant. 66, 1193, 1998; Cancer, 80, 1141, 1997)。我々は 104 匹の CD-1 mice (female, 7 週齢) の背部を剃毛後、initiator, DMBA と promoter, TPA を塗布する発癌実験系 (Jpn J Cancer Res, 91, 579, 2000) に FK506 を併用塗布して、FK506 の発癌性を検索した。結果は、14 w までは (1) DMBA+TPA の実験系に (2) DMBA+TPA+FK506 の系より発癌が多い傾向であったが、14 w 以降では、(2) の系に (1) の系より著しい腫瘍の増加がみられた ( $0.47 \pm 0.13$  vs.  $0.10 \pm 0.025$ )。また、TPA を塗布しない DMBA に FK506 のみを加えた系においても 26 匹中 4 匹に腫瘍が発生した (2 匹が悪性、2 匹が良性)。また、発生した腫瘍中 8.0% が squamous cell carcinoma で、その他は papilloma であった。以上の実験より、14 w までは、FK506 は癌の抑制に働き、14 w 以降は、個体の発癌を抑制する NK cell を叩く方に作用したと推測される。移植臓器を拒否しようとする正常な自己の NK cell, CD4 細胞を叩く薬剤は、感染にのみならず発癌に対する自己の抵抗力も抑え、これを何年も治療を続け、生命を脅かすアトピー性皮膚炎に使用する事は一考を要する。

### 375 ダニ抗原反復塗布による皮膚炎モデルの免疫病理学的研究—第 1 報 モデルの作製について—

筑本貴郎 中村伸昭 布施田和紀 田中宏幸  
 稲垣直樹 永井博之  
 (岐阜薬科大学 薬理学教室)

【目的】アトピー性皮膚炎 (AD) は湿疹様症状と掻痒を主徴とする難治性疾患である。その病態解析にはマウスを用いた皮膚炎モデルが有用であると思われる。本研究では BALB/c マウスと NC/Nga マウスにダニ抗原を反復塗布して生じるマウス皮膚炎モデルについて検討した。【方法】マウスの両耳介の表裏をテープストリッピングし、ダニ抗原溶液を塗布した。ダニ抗原は週 1 回、計 5 回塗布し、経時的に耳介の厚さを評価した。血清中総 IgE 値は ELISA 法を用いて、耳介およびリンパ節におけるサイトカイン mRNA の発現は RT-PCR 法を用いて測定した。【結果】テープストリッピングにより、皮膚炎症状の増悪がみられた。また、ダニ抗原の 5 回目の塗布後にはいずれのマウスにも二相性の耳介腫脹が誘発された。さらに、いずれのマウスにおいても血清中総 IgE 値の上昇とともに、IL-4 mRNA 発現の増強が認められ、IFN-γ mRNA 発現は逆に低下した。【結論】本モデルは表皮が欠損した重症の皮膚炎モデルと考えられ、反復抗原刺激をすることにより、Th1/Th2 バランスが Th2 側へシフトして、IgE 産生の増大がみられる。今後、本モデルを用いて AD の病態解明、治療薬の探索に応用したいと考えている。

### 376 ダニ抗原反復塗布による皮膚炎モデルの免疫病理学的研究—第 2 報 薬物の影響について—

布施田和紀 中村伸昭 筑本貴郎 田中宏幸  
 稲垣直樹 永井博之  
 (岐阜薬科大学 薬理学教室)

【目的】アトピー性皮膚炎の病態解析および治療薬の検索にはダニ抗原誘発皮膚炎モデルが有用であると思われる。本研究では表皮を剥離した皮膚にダニ抗原を反復塗布して作成したマウス重症皮膚炎モデルを確立し、漢方方剤および他の薬物の影響を検討した。【方法】NC/Nga マウスの両耳介の表裏をテープストリッピングし、ダニ抗原溶液を塗布した。ダニ抗原は週 1 回、計 5 回塗布し、種々の時間に耳介の厚さを測定した。血清中総 IgE 値は ELISA 法で、耳介およびリンパ節におけるサイトカイン mRNA の発現は RT-PCR 法で検討した。薬物は連日経口投与した。【結果】テープストリッピングしたマウスにダニ抗原を塗布して生じる皮膚炎は Th2 依存性が強く、重症のアトピー性皮膚炎のモデルとなりうるものと思われた。漢方方剤の十全大補湯は 300 mg/kg で、また、Prednisolone は 3mg/kg で耳介腫脹を有意に抑制した。【結論】NC/Nga マウス耳介にダニ抗原を反復塗布して誘発する皮膚炎は Th2 優位な背景を持ち、アトピー性皮膚炎の一面を反映するモデルとして有用であると思われる。また、十全大補湯は本皮膚炎を抑制することから、アトピー性皮膚炎治療への適用の可能性が示唆される。

BEST AVAILABLE COPY

COPY

Attachment 3

375 Immunopharmacological study of animal model of dermatitis with repetitive application of mite antigen – the first edition construction of animal model –

T. Chikumoto , N. Nakamura, K Fuseda, H. Tanaka, N. Inagaki and H. Nagai  
(Department of Pharmacology, Gifu Pharmaceutical University)

[Object]

Atopic dermatitis (AD) is one of the inveterate diseases, which is mainly characterized by eczema and pruritus. Animal models of dermatitis seem to be useful for analyzing the pathogenesis of atopic dermatitis. In this study, we investigated animal models of the dermatitis caused by repetitive application with mite antigen using NC/Nga mice and BALB/c mice.

[Methods]

The ears of mice were stripped with tape, and applied with mite antigen solution five times, once a week. The ear thickness was sequentially measured. Serum total IgE concentration was quantified with ELISA, and an expression of cytokines mRNA in the ears and lymph nodes were calculated with RT-PCR.

[Results]

The symptoms of dermatitis exacerbated by using the tape-stripping. Biphasic ear thickening was induces after the fifth application of mite antigen. In each mice, Furthermore, in each mice, as increasing of serum total IgE concentration, an expression of IL-4 mRNA was increased, whilst an expression of IFN- $\gamma$  mRNA were decreased.

[Conclusion]

We considered this model as a severe dermatitis model with desquamation of epidermis. Repetitive stimulation by mite antigen induced Th2 elevation of Th1/Th2 balance with the up-regulation of IgE production. From now on, the further analysis of pathogenesis of atopic dermatitis and the screening of new drug for atopic dermatitis will be done using this model.

BEST AVAILABLE COPY

**COPY**

376 Immunopharmacological study of animal model of dermatitis with repetitive application of mite antigen – the second edition the efficacy of the drug of atopic dermatitis –

K. Fuseda, N. Nakamura, T. Chikumoto, H. Tanaka, N. Inagaki and H. Nagai  
(Department of Pharmacology, Gifu Pharmaceutical University)

**[Object]**

Animal model of dermatitis induced by mite antigen seems to be useful for the analysis of pathogenesis of atopic dermatitis and the screening of new drug for atopic dermatitis. In this study, we established a severe dermatitis mice model by repetitive application of mite antigen on epidermis detached skin, and investigated the effect on the animal model of Chinese medicine and other drug.

**[Methods]**

The two sides of ears of NC/Nga mice were stripped with tape, and applied with mite antigen solution five times, once a week. The ear thickness was sequentially measured. Serum total IgE concentration was quantified with ELISA, and an expression of cytokines mRNA in the ears and lymph nodes were calculated with RT-PCR. Drugs were orally administrated every day.

**[Results]**

The dermatitis caused by repetitive application of mite antigen on the tape stripped mouse showed Th2 dependency, and it was thought as the model of severe atopic dermatitis. 300mg/kg of Juzen-Daiho-To, one of Chinese medicine, and 3mg/kg of prednisolone significantly suppressed the ear thickening.

**[Conclusion]**

The dermatitis model repeatedly applied with mite antigen on ears of NC/Nga mice showed the Th2 dependent background. It can be considered to be useful as an animal model reflecting the one aspect of atopic dermatitis. As Juzen-Daiho-To suppressed the dermatitis, it suggests that it might be effective for the human atopic dermatitis.

**BEST AVAILABLE COPY**

**COPY**